SCHEMBL3236227

SCHEMBL3236227

CCCn1c(=O)n(Cc2ccc(Cl)c(Cl)c2)c(=O)c2c1nc(CC)n2C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
TP53 P04637 2/20 0.58
SMN1; SMN2 Q16637 5/20 0.55
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
LMNA P02545 2/20 0.54
STAT6 P42226 1/20 0.54
ALDH1A1 P00352 3/20 0.52
HPGD P15428 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
TSHR P16473 2/20 0.52
HTT P42858 2/20 0.52
KMT2A Q03164 1/20 0.52
MTHFD2 P13995 1/20 0.51
HIF1A Q16665 2/20 0.50
PKM P14618 1/20 0.49
CYP2D6 P10635 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238927 0.90 SMN1; SMN2 (0.54) MAPTTP53SMN1; SMN2CYP1A2CYP3A4
SCHEMBL3232406 0.89 MAPT (0.52) MAPTTP53SMN1; SMN2CYP1A2CYP3A4
SCHEMBL3238173 0.89 MAPT (0.55) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL3241806 0.86 MAPT (0.49) MAPTTP53SMN1; SMN2CYP1A2CYP3A4
SCHEMBL3235666 0.86 ADORA3 (0.58) MAPTTP53SMN1; SMN2ALDH1A1HPGD
SCHEMBL3227315 0.85 ADORA3 (0.48) MAPTTP53LMNAADORA2AADORA2B
SCHEMBL3221616 0.85 ADORA1 (0.55) MAPTLMNASTAT6ALDH1A1HPGD
SCHEMBL3231844 0.84 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1HIF1AADORA2AADORA2B
SCHEMBL3234639 0.83 MAPT (0.55) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL3224011 0.83 ADORA3 (0.60) MAPTLMNAALDH1A1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP claimed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US claimed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO claimed
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023704-A1 Novel Compounds 737 GRPR, GABRB1, GABBR1 MAPT 2910/4885TP53 4885/4885SMN1; SMN2 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.